{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:27:48Z","timestamp":1793932068637,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xkme.2026.101516","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:56:01Z","timestamp":1788796561000},"page":"101516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible\u2014or Not Too Late to Start?"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-9691","authenticated-orcid":false,"given":"Masayuki","family":"Yamanouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1016\/j.xkme.2026.101516_bib1","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"5S","key":"10.1016\/j.xkme.2026.101516_bib2","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2026.101516_bib3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.xkme.2026.101516_bib4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2026.101516_bib5","first-page":"S246","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.xkme.2026.101516_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2026.101516_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.xkme.2026.101516_bib8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5-6","key":"10.1016\/j.xkme.2026.101516_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000531000","article-title":"Discontinuation of renin-angiotensin system inhibitors and clinical outcomes in chronic kidney disease: a systemic review and meta-analysis","volume":"54","author":"Tang","year":"2023","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2026.101516_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials","volume":"177","author":"Ku","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xkme.2026.101516_bib11","article-title":"Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study","volume":"55","author":"Yang","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.xkme.2026.101516_bib12","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41440-025-02218-8","article-title":"Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation","volume":"48","author":"Hashimoto","year":"2025","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1016\/j.xkme.2026.101516_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.3680","article-title":"Discontinuation of RAS inhibition after an acute decline in estimated glomerular filtration rate","volume":"9","author":"Ku","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.xkme.2026.101516_bib14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1681\/ASN.0000000000000425","article-title":"Estimated effect of restarting renin-angiotensin system inhibitors after discontinuation on kidney outcomes and mortality","volume":"35","author":"Hattori","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"10.1016\/j.xkme.2026.101516_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.xkme.2026.101516_bib16","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101516_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2026.101516_bib18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2026.101516_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.xkme.2026.101516_bib20","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/ejhf.70093","article-title":"Sodium-glucose co-transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular-kidney- metabolic conditions: a pooled analysis of randomized trials","volume":"27","author":"Ferreira","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.xkme.2026.101516_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101516_bib22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101516_bib23","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101516_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/M23-1874","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for dialysis and cardiovascular disease in patients with stage 5 chronic kidney disease","volume":"177","author":"Yen","year":"2024","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.xkme.2026.101516_bib25","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00125-024-06257-7","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease","volume":"67","author":"Lin","year":"2024","journal-title":"Diabetologia"},{"issue":"23","key":"10.1016\/j.xkme.2026.101516_bib26","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.xkme.2026.101516_bib27","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2026.101516_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.xkme.2026.101516_bib29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101516_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100251","article-title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL\/min\/1.73 m2","volume":"19","author":"Mima","year":"2023","journal-title":"Metabol Open"},{"issue":"1","key":"10.1016\/j.xkme.2026.101516_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2337\/cd24-0036","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease: clinical evidence and potential adverse events","volume":"43","author":"Upadhyay","year":"2024","journal-title":"Clin Diabetes"},{"issue":"7","key":"10.1016\/j.xkme.2026.101516_bib32","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ekir.2025.04.012","article-title":"Finerenone and estimated GFR slope in type 2 diabetes and CKD","volume":"10","author":"Yamanouchi","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.xkme.2026.101516_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jacc.2025.05.038","article-title":"Blinded withdrawal of finerenone after long-term treatment in the FINEARTS-HF trial","volume":"86","author":"Vaduganathan","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101516_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.xkme.2026.101516_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101516_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"2","author":"Tuttle","year":"2020","journal-title":"Kidney360"},{"issue":"10","key":"10.1016\/j.xkme.2026.101516_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101516_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101516_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf172","article-title":"Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting","volume":"18","author":"Hsiao","year":"2025","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.xkme.2026.101516_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101516_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.xkme.2026.101516_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101516_bib42","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2215\/CJN.0000000000000526","article-title":"Reframing chronicity with urgency in chronic kidney disease management","volume":"19","author":"Neuen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101516_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mra compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:34:43Z","timestamp":1793928883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2590059526002785"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101516","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible\u2014or Not Too Late to Start?","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101516"}}